Abstract
Linking two pharmacophores that bind different cell surface receptors into a single molecule can enhance cell-targeting specificity to cells that express the complementary receptor pair. In this report, we developed and tested a synthetic multivalent ligand consisting of glucagon-like peptide-1 (GLP-1) linked to glibenclamide (Glb) (GLP-1/Glb) for signaling efficacy in β-cells. Expression of receptors for these ligands, as a combination, is relatively specific to the β-cell in the pancreas. The multivalent GLP-1/Glb increased both intracellular cAMP and Ca2+, although Ca2+ responses were significantly depressed compared with the monomeric Glb. Moreover, GLP-1/Glb increased glucose-stimulated insulin secretion in a dose-dependent manner. However, unlike the combined monomers, GLP-1/Glb did not augment insulin secretion at nonstimulatory glucose concentrations in INS 832/13 β-cells or human islets of Langerhans. These data suggest that linking two binding elements, such as GLP-1 and Glb, into a single bivalent ligand can provide a unique functional agent targeted to β-cells.
Original language | English (US) |
---|---|
Pages (from-to) | C48-C56 |
Journal | American Journal of Physiology - Cell Physiology |
Volume | 316 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2019 |
Keywords
- Cell targeting
- Diabetes
- GLP-1
- GPCR signaling
- Incretin
- Multivalent
- Sulfonylurea
- β-cell
ASJC Scopus subject areas
- Physiology
- Cell Biology